In the last three years, particularly from 2014 to 2017, there has been a significant spike in the number of calls that are being made in the U.S. that are related to the poison control. And it seems that there is a direct link between the increase in the calls and an antidepressant drug that is not yet approved, making it illegal. The drug is called Tianeptine, and the misuse and international abuse of the same has put a lot of people in serious trouble, not just legally, but health-wise as well.
The fact there is a link between the two aforementioned factors was confirmed by the US Centers for Disease Control and Prevention, on this Thursday. The drug is being marketed as Stablon or Coaxil, and is typically used as an antidepressant in not just Latin America, but in the Asian and European regions as well. Despite the fact that the US Food and Drug Administration has not yet approved the drug, it is still being sold on the internet.
The use of this drug is said to have some serious side effects that include confusion, vomiting, kidney failure and can be very lethal. There were some deaths reported outside the U.S. that have a direct connection with the misuse of this drug called tianeptine. Recently, two deaths in the U.S. as well were linked to the tianeptine toxicity, after the online purchase of this drug.
Speaking of drug abuse, recently it was found in a report that drug abuse accompanied with mental health issues are a huge point of concern in the DuPage County. These are considered as the top concerns in the region because of the severity and the large number of people it is linked to. According to the report, drug abuse contributes for 44 percent while the mental health problems contribute for nearly 43 percent.
Sasha Farrell is a privileged and versatile content writer and editor in the domains of Pharma, Health, and Medical. Before getting into the writing world, Sasha was working as an STM editor for few renowned authors and publications, which gave head-start to rifle through the Pharma, Health, and Medical Innovations.